fda submission

Clinical Research Solutions

Pedaling While Fixing a Flat: Conducting a Good FDA Meeting Under Bad Circumstances

Before using a significant risk medical device in a clinical study, Sponsors must first obtain FDA approval. Frequently, the request for an investigational device exemption (IDE) is disapproved, and...

Clinical Research Solutions

Why It's Smarter to Play the Long Game When Planning Your FDA Submission

The drug development process is long and expensive. You are doing yourself and your product a huge advantage if you enter and go through the process with a well-researched plan. When planning your...

Clinical Research Solutions

Only 12% of Generic Drugs Reviewed Were Approved in the 1st Review Cycle, says GAO Report

On August 7th, the U.S. Government Accountability Office (GAO) published its report on generic drug applications. In the report, GAO comments on the number of products approved on the first review...

Clinical Research Solutions

FDA Issues Draft Guidance to Advance Development of Combination Products

On Tuesday, February 5th, FDA published a draft guidance explaining the principles for premarket review of combination products, including how to determine which type of premarket submission is...

Clinical Research Solutions

FDA Draft Guidance on Tentatively Approved ANDA Submissions

FDA Draft Guidance on Tentatively Approved ANDA Submissions: On Wednesday, January 16th, the FDA published its first draft guidance since the partial government shutdown took effect on December 22,...

Regulatory Sciences

FDA Advances its Biosimilar Policy Framework

On Tuesday, December 11th, FDA made large strides to advance its biosimilar policy framework, including the release of four guidance documents and a proposed rule. Through these guidance documents,...

Clinical Research Solutions

FDA Takes Steps to Promote Digital Tools for Prescription Drugs

On Tuesday, November 20th, FDA announced the establishment of a public docket to solicit comments and feedback on a proposed framework regarding the regulation of prescription drug-use-related...

Clinical Research Solutions

FDA Seeks Feedback on Surrogate Endpoint Table

On December 13, 2016, the 21st Century Cures Act was signed into law with the intention of speeding FDA’s approval time for drugs and medical devices. When signed, the Cures Act increased FDA’s...

Clinical Research Solutions

FDA Issues Final Guidance Regarding Content & Format Requirements for ANDA Submissions

On Tuesday, September 25th, the FDA issued a guidance document entitled “ANDA Submissions – Content and Format.” The document, initially issued as a draft guidance in June 2014, provides sponsors...

Clinical Research Solutions

Good Review Management Principles & Practices, Part Two: Operational Principles

Details on the fundamental values outlined on FDA’s GRMP draft guidance are available in our preceding article, entitled “Good Review Management Principles & Practices, Part One: Fundamental Values"...

1 2